Ocular allergy/inflammation:
Indications for: LOTEMAX
Steroid-responsive ocular diseases. Post-op inflammation after ocular surgery.
Clinical Trials:
Post-Operative Inflammation
- Placebo-controlled clinical studies demonstrated that Lotemax is effective for the treatment of anterior chamber inflammation as measured by cell and flare.
Giant Papillary Conjunctivitis
- Placebo-controlled clinical studies demonstrated that Lotemax was effective in reducing the signs and symptoms of giant papillary conjunctivitis after 1 week of treatment and continuing for up to 6 weeks while on treatment.
Seasonal Allergic Conjunctivitis
- A placebo-controlled clinical study demonstrated that Lotemax was effective in reducing the signs and symptoms of allergic conjunctivitis during peak periods of pollen exposure.
Uveitis
- Controlled clinical studies of patients with uveitis demonstrated that Lotemax was less effective than prednisolone acetate 1%. Overall, 72% of patients treated with Lotemax experienced resolution of anterior chamber cell by day 28, compared to 87% of patients treated with 1% prednisolone acetate. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with Lotemax and 6% with prednisolone acetate 1%.
Adult Dosage:
Steroid-responsive diseases: 1–2 drops into affected eye(s) 4 times daily. May give up to 1 drop every 1hr within the 1st week of therapy. Post-op: 1–2 drops into operated eye(s) 4 times daily beginning 24hrs after surgery, continue for 2wks post-op.
Children Dosage:
Not established.
LOTEMAX Contraindications:
Ocular fungal, viral, or mycobacterial infections.
LOTEMAX Warnings/Precautions:
Reevaluate if no improvement after 2 days. Prescribe initially and renew only after appropriate exam. Corneal or scleral thinning. Glaucoma. History of herpes simplex. Monitor IOP and for secondary infections in prolonged therapy (>10 days). Avoid abrupt cessation. Contact lenses (remove during therapy and when eyes are inflamed). Pregnancy. Nursing mothers.
LOTEMAX Classification:
Steroid.
Adverse Reactions:
Local reactions (eg, blurred vision, burning, itching, dry eye), photophobia, headache, rhinitis, pharyngitis. May mask or exacerbate ocular infections. Prolonged use may increase: IOP, optic nerve damage, visual acuity and field defects, cataract formation, corneal perforation. May delay healing and increase bleb formation after cataract surgery; also, Oint/Gel: anterior chamber inflammation, conjunctival hyperemia, corneal edema, eye pain.
Drug Elimination:
Fecal.
How Supplied:
Susp—5mL, 10mL, 15mL, Oint—3.5g; Gel—5g